InMed amends merger with Mentari; files S-4; clarifies name change, redomestication, tax treatment

InMed Pharmaceuticals Inc.

Amendment clarifies sequencing: InMed will change name to Mentari Therapeutics and redomesticate to Nevada before closing.
Amendment introduces Company PIPE Amendment concept to facilitate additional pre-closing financing and clarifies impact on exchange ratio.
Tax treatment clarified: First and Second Mergers intended to qualify as a reorganization under Section 368(a) of the IRC.
Merger expected to close in Q4 2026, subject to shareholder approvals, S-4 effectiveness, and other conditions.
InMed filed Form S-4 on July 2, 2026, containing preliminary proxy statement/prospectus and management information circular.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.